Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nephro Care IndiaNSE:NEPHROCARE +2.29%48 EBITDA Margin % is 13.75% as of Mar. 2026, which is 3% below its 10-year median of 14.23. GuruFocus rates NSE:NEPHROCARE with a GF Score™ of 48/100. The stock has 2 warning signs investors should review. Among 672 Healthcare Providers & Services companies, Nephro Care India ranks better than 52.53% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nephro Care India's EBITDA for the
six
months ended in Mar. 2026 was ₹28.5 Mil. Nephro Care India's Revenue for the
six
months ended in Mar. 2026 was ₹207.5 Mil. Therefore, Nephro Care India's EBITDA margin for the quarter that ended in Mar. 2026 was 13.75%.
Nephro Care India (NSE:NEPHROCARE) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Nephro Care India EBITDA Margin % Related Terms
Nephro Care India EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Nephro Care India's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:NEPHROCARE vs HCA, THC, EHC: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Nephro Care India's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nephro Care India EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Nephro Care India's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Nephro Care India's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nephro Care India (NSE:NEPHROCARE) has a EBITDA Margin % of 13.75% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nephro Care India and its competitors. This is near median its historical median of 14.23. Over the past decade, Nephro Care India's EBITDA Margin % has ranged from 3.69 to 24.80. According to the industry distribution chart, Nephro Care India ranks #319 out of 672 companies in the Healthcare Providers & Services industry, placing it in the top 47.5%.
Is Nephro Care India's EBITDA Margin % too high?
Nephro Care India's current EBITDA Margin % of 13.75% is near median its 10-year median of 14.23. Over the past 10 years, this metric has ranged from a low of 3.69 to a high of 24.80. The Healthcare Providers & Services industry median EBITDA Margin % is 10.18. Nephro Care India's value of 13.75% is 35.1% above this industry median. Based on the distribution chart, Nephro Care India ranks #319 out of 672 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Nephro Care India has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Nephro Care India's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Nephro Care India ranks #319 out of 672 companies for EBITDA Margin %. This puts Nephro Care India in the upper half of its industry. The industry median EBITDA Margin % is 10.18. Nephro Care India's value of 13.75% is 35.1% above this benchmark. Historically, Nephro Care India's own EBITDA Margin % has ranged from 3.69 to 24.80 over the past decade. While the company's 10-year median is 14.23 vs. the industry median of 10.18, Nephro Care India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.18, based on 672 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nephro Care India's current EBITDA Margin % of 13.75% is 35.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nephro Care India and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nephro Care India's current EBITDA Margin % is 13.75%, which is near median its own 10-year median of 14.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nephro Care India stock overvalued right now?
Nephro Care India (NSE:NEPHROCARE) has a current EBITDA Margin % of 13.75%. The current EBITDA Margin % is 13.75%, which is near median its 10-year median of 14.23 and 35.1% above the Healthcare Providers & Services industry median of 10.18. Nephro Care India's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nephro Care India (NSE:NEPHROCARE), the current EBITDA Margin % is 13.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nephro Care India Ltd is a Kolkata-based healthcare provider specializing in comprehensive medical services for renal patients. The company serves as a one-stop treatment center, offering a broad spectrum of clinical and lifestyle solutions, along with specialized treatments for renal insufficiency. Its holistic care framework addresses not only the medical and physiological aspects of treatment but also focuses on lifestyle and spiritual wellness, providing an integrated approach to patient care.
48GF Score
Get the complete analysis for NSE:NEPHROCARE
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NEPHROCARE has been successfully added to your 
